Unanimous Thumbs-Up From FDA Advisors for Alzheimer’s Drug

Source link :

An FDA advisory committee on Monday unanimously supported the investigational drug donanemab for treating early Alzheimer’s disease. In an 11-0 vote, the Peripheral and Central Nervous System Drugs Advisory Committee said the benefits of donanemab outweighed its risks for the population of Alzheimer’s disease patients with mild cognitive impairment and mild dementia enrolled in the […]

Author : News Health

Publish date : 2024-06-10 21:34:42

Copyright for syndicated content belongs to the linked Source.